Aidoc vs Causaly

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Aidoc employs 300 people, while Causaly has 1-50 employees.

Aidoc has raised $370M in disclosed funding across 8 known rounds. Causaly's funding history is not publicly available.

Aidoc holds the higher Awaira Score at 67/100, compared to Causaly's 45/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 22-point gap that reflects meaningful differences in scale or traction.

Aidoc was founded by Elad Walach in 2016. Causaly was founded by Elias Iosif in 2018. Visit each company's profile on Awaira for a full founder biography.

Aidoc: Aidoc is an Israeli artificial intelligence company founded in 2016 that develops clinical decision support software for radiology and medical imaging. The platform uses deep learning algorithms to analyze medical images, prioritize critical findings, and alert radiologists to potential abnormalities, particularly focusing on conditions requiring urgent intervention. Aidoc's core offering integrates into existing hospital workflows and PACS systems, enabling radiologists to identify and triage high-risk cases more efficiently. The company operates in the clinical AI segment, competing with firms like Zebra Medical Vision and Enlitic in automated imaging analysis. Aidoc's technology addresses the growing bottleneck of radiologist workload and diagnostic delays by automating preliminary image screening and flagging priority cases. The platform reportedly covers multiple pathologies including stroke, pulmonary embolism, and other acute conditions. As of the latest available data, Aidoc has secured $370 million in total funding through Series D stage, though its valuation remains not disclosed. The company has expanded internationally and serves healthcare institutions across multiple regions. Aidoc's growth trajectory reflects increasing institutional adoption of AI-assisted diagnostic tools in radiology departments globally, driven by workforce shortages and demand for faster diagnostic turnaround times in clinical settings. Aidoc focuses on clinical workflow integration rather than replacement, embedding AI directly into existing radiology infrastructure to accelerate diagnostic processes. Causaly: Causaly built a biomedical AI platform that extracts and maps causal relationships from scientific literature at scale, allowing pharmaceutical researchers and scientists to query cause-and-effect relationships across millions of published papers and clinical documents. The platform used a specialised natural language processing system trained to identify causal assertions in biomedical text, producing a structured knowledge graph of disease mechanisms, drug targets, and biological pathways.\n\nThe company was founded in London in 2018 and was acquired by Elsevier, the academic publishing giant, in 2022. The acquisition gave Elsevier an AI layer to sit atop its vast corpus of scientific publications, enabling researchers using ScienceDirect and other Elsevier products to query causal biological knowledge rather than simply searching for documents. Prior to acquisition, Causaly had built a client base among pharmaceutical R&D teams seeking to accelerate literature review and hypothesis generation.\n\nCausaly represented a niche but strategically important segment of the biomedical AI market: causal reasoning and knowledge graph construction. Its acquisition by Elsevier followed a broader trend of academic publishers acquiring AI startups to enhance their platforms, similar to Wiley acquiring Atypon and Springer Nature building AI discovery tools. The company is now integrated into Elsevier Research Intelligence, extending causal AI capabilities to Elsevier institutional subscribers worldwide.

Aidoc was founded first in 2016, giving it 2 years of additional market experience. Causaly was founded later in 2018. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Aidoc has approximately 300 employees, while Causaly has approximately 1-50. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Aidoc and Causaly are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.